ArticleClinical ophthalmology (Auckland, N.Z.)2009
Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics.
Article in Clinical ophthalmology (Auckland, N.Z.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 2 syntheses or guidelines pooled it, 192 citations in OpenAlex.
- Corneal collagen cross-linking for bacterial infectious keratitis.The Cochrane database of systematic reviews · 2020Pooled it
- Bacterial profile of ocular infections: a systematic review.BMC ophthalmology · 2017Pooled it
- Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.Clinical drug investigation · 2012Trial
- UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2012Trial
- Beyond the Barrier: Overcoming Ocular Antimicrobial Resistance Through AI and Novel Therapeutics.International journal of molecular sciences · 2026Review
- In vivo tolerability of topical telavancin versus vancomycin in a murine ocular model.The Journal of antimicrobial chemotherapy · 2026Article
- Culture-proven endophthalmitis associated with Boston Type I keratoprosthesis: clinical features, microbiologic aspects, and outcomes.Journal of ophthalmic inflammation and infection · 2026Article
- The In Vitro Antibacterial Effects of Genipin Against Pathogens Commonly Associated With Infected Ulcerative Keratitis: A Canine Preliminary Study.Investigative ophthalmology & visual science · 2026Article
- Mechanisms and Evolution of Antimicrobial Resistance in Ophthalmology: Surveillance, Clinical Implications, and Future Therapies.Antibiotics (Basel, Switzerland) · 2025Review
- Cefiderocol and Moxifloxacin Have Additive and Synergistic Activity Against Pseudomonas aeruginosa Including an Isolate of the 2023 Keratitis Outbreak.Investigative ophthalmology & visual science · 2025Article
- In Vitro Activity of Bacteriophages Against Ocular Methicillin-resistant S. aureus Isolates Collected in the US.Ophthalmology and therapy · 2025Article
- Paediatric Utilisation of Ophthalmic Antibiotics in the Ear in Aotearoa/New Zealand.Children (Basel, Switzerland) · 2025Article
- Conservative management of paediatric dacryocystitis: a collection of clinical experiences highlighting effectiveness and parental satisfaction.Drugs in context · 2025Article
- Antimicrobial and antifouling hyaluronic acid-cobalt nanogel coatings built sonochemically on contact lenses.Ultrasonics sonochemistry · 2024Article
- Formulation of Thermo-Sensitive In Situ Gels Loaded with Dual Spectrum Antibiotics of Azithromycin and Ofloxacin.Polymers · 2024Article
- An Analysis of the Use of Topical Ocular Anti-Infectives in Galicia (Spain) between 2020 and 2023.Diseases (Basel, Switzerland) · 2024Article
- Odontogenic Orbital Cellulitis at the Crossroads of Surgeries: Multidisciplinary Management and Review.Diagnostics (Basel, Switzerland) · 2024Article
- Untargeted and temporal analysis of retinal lipidome in bacterial endophthalmitis.Prostaglandins & other lipid mediators · 2024Review
- Characterization of the resistome and predominant genetic lineages of Gram-positive bacteria causing keratitis.Antimicrobial agents and chemotherapy · 2024Article
- Microbiology and management of Staphylococcus aureus lacrimal system infections: A 10-year retrospective study.PloS one · 2024Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis article reviews the effects of the increase in bacterial resistance on the treatment of ocular infections.
designInterpretive assessment.
methodsLiterature review and interpretation.
resultsOcular bacterial infections include conjunctivitis, keratitis, endophthalmitis, blepharitis, orbital cellulitis, and dacryocystitis. Treatment for most ocular bacterial infections is primarily empiric with broad-spectrum antibiotics, which are effective against the most common bacteria associated with these ocular infections. However, the widespread use of broad-spectrum systemic antibiotics has resulted in a global increase in resistance among both Gram-positive and Gram-negative bacteria to a number of the older antibiotics as well as some of the newer fluoroquinolones used to treat ophthalmic infections. Strategies for the prevention of the increase in ocular pathogen resistance should be developed and implemented. In addition, new antimicrobial agents with optimized pharmacokinetic and pharmacodynamic properties that have low toxicity, high efficacy, and reduced potential for the development of resistance are needed.
conclusionsNew antimicrobial agents that treat ocular infections effectively and have a low potential for the development of resistance could be a part of strategies to prevent the global increase in ocular pathogen resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.